Pharmabiz4h
EMA committee recommends Novo Nordisk’s Wegovy label update to reflect reduced heart failure symptoms and improved physical function
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...
HealthDay on MSN15h
Endovascular Therapy Improves Left Ventricular Diastolic Function in HFpEF
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
TCTMD19h
Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF
When surveyed, many physicians said the belief that patients had adequate symptom control was why they didn’t add more meds.
EU regulator backs use of Novo’s Wegovy for obesity-related heart condition
EMA endorses Novo Nordisk's Wegovy for treating heart failure and lowering heart risks in obese patients. Second approval ...
Endovascular therapy improves left ventricular diastolic function in heart failure with preserved ejection fraction
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...
Novo’s Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next.
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.